Thank you, Henrik. I will now talk a bit about the status of our European commercialization in general, followed by a deep dive into the dynamics, potential, and challenges of our three focus markets, with a particular focus on Germany. We expect that increasing our focus on Germany, Spain, and Italy will be enough to drive profitability by the end of 2026. The drivers of growth are that we have innovative pricing negotiated in Germany and Spain, and we do see encouraging progress in Italy according to our plans. We have also recently received national guideline updates in Germany and Spain. We observe an increased positive clinical experience. KOL advocacy, peer to peer exchange, and increased awareness. Advocacy, peer-to-peer exchange, and increased awareness. In Germany, we are already accessing 80% of healthcare regions, and in Spain, which is encouraging for sales pick-up in the second half of 2024 and the beginning of 2025. The graph displays our sales trajectory in revenue quarter over quarter, starting from the first quarter of 2023 up until the third quarter of 2024. We do see a clear positive growth trend, with variations informed by different factors across different quarters. In Q3, we did see strong growth in Spain, both in revenue and in sales. We did see a small increase in Germany in both revenue and sales. In fact, between Spain and Germany, we saw double-digit growth in sales, partly due to the decline in Greece. This was not fully translated into revenue, but still speaks to the growing demand in two of our key markets. Our European commercialization case is based on that. Oncopeptides has a fully approved drug for the treatment of an incurable disease, providing an expanding market opportunity valued at 1.5 billion SEK. Our focus right now is on growing sales in the markets where we have secured access, and on adding diversity to our revenue stream by unlocking new markets and finding partnerships for our geographic expansion. There are different steps in the market access process, and let me remind you of that. The timelines for the review and negotiation phases are country-specific and are, at large, controlled by payers. Since our quarterly update, we have progressed really well with Spain and we are now in the last phase of market access, which is to obtain regional access. And I said we have ensured access in record time. Approximately 80% of Spain. This has been achieved in such a short time, due to the high unmet need and the foundation of a positive clinical experience, generating demand for Pepaxti. I will speak even more about Spain in a little while. Italy has moved into the price negotiation phase and we are progressing according to our plan. Regarding the Netherlands, the payer environment is strict. There are intense discussions on how to get any new multiple myeloma drugs reimbursed. These restrictions will delay time to market for all drugs, and we have decided to put our efforts on hold until we see improved willingness to pay. This is unfortunate, but it is out of our control. We still see long-term potential in this market, but right now, we have decided to adjust our investment to the markets where we have access. We will have to carefully follow the development to make an informed decision on when to restart our efforts. Should we completely remove the market from our launch plan? We will, of course, clearly communicate that, and that is not the case here.
We are strengthening our focus on the markets that we believe have the potential to make a true difference and bring us to profitability by the end of 2026. And I will now give an overview of these three markets with an emphasis on Germany. What is very apparent when you take a look at the three key markets for Oncopeptides next to each other, is the lack of clinical experience we had in Germany when launching Pepaxti. We are working hard to catch up. At the same time, the potential for a stronger sales pickup in markets where we have clinical experience is confirmed by the start in Spain. We, in addition, have had similar positive clinical experience pre-launch in Italy, from both key opinion leaders and early access programs and investigators, which we believe will support the launch from a prescriber perspective. Germany is the most scattered market, while Spain and Italy are more centralized. Regarding the size of the different target populations, Germany is the largest, followed by Italy, and then Spain. Now I wish to give you a better understanding of the dynamics. The critical success factors and opportunities in Germany. But first, if we boil it down to what really matters with a product like Pepaxti, I will repeat myself. It's all about generating a positive clinical experience that demonstrates the value of the drug. And we do have the opportunity, as we see physicians continue to prescribe Pepaxti. There are many patients who cannot tolerate or will not respond to immunotherapy and are in need of an option that provides a balance of clinically meaningful efficacy, tolerability, and quality of life. Looking at the different barriers, critical success factors, and opportunities in Germany. As said, we only had one key opinion leader with very limited clinical experience at launch in Germany. The critical success factor here is to ensure that key opinion leaders do get a positive clinical experience to be able to recommend and advocate for the drug. As of today, we have managed to get nine out of 17 key opinion leaders to gain a positive clinical experience. And I will show you a bit later what effect that can have on a territory. The first national guideline update since we launched has just occurred, and we know that we are included in the guidelines as the draft was recently presented and impacted, including our inclusion. This will, of course, also support the launch as all the medical education meetings are reviewing the guidelines. We had no clinical experience at launch among the prescribing physicians in hospitals or in office-based settings. In Germany, physicians commonly listen to their colleagues, and peer-to-peer exchange is critical to success. And as Pepaxti is a product that generates a positive clinical experience, peer-to-peer exchange is increasing in everyday practice. We have observed several local protocols and guidelines being updated, and we actively publish case reports to disseminate the experience generated. Germany is a very scattered market with many treating physicians, which makes it even more difficult to build clinical experience from the start of a launch. The key to success in such a market is, as I already mentioned, to gain KOL advocacy. This is a heat map of Germany, showing the population density of persons 65 years and older. That is the age of our patients. The bubbles in orange show the cumulative number of Pepaxti since launch until the end of the third quarter 2024 by ordering pharmacy location. As you can see, we are focusing on the most population-dense areas and in the regions where we generate clinical experience, and where we have key opinion leaders and key accounts, sales uptake is growing and accelerating. Regions began to generate experience in the second half of 2023, and these are now responsible for the majority of sales. We have also seen several regions start to gain experience in the second and third quarters of 2024, and we are expecting them to increase in the coming six months. Let's take a closer look at this. This graph shows five of the largest territories with the most dense population. And as you can see, there is a clear difference in regions one, two, and five. We have obtained sales and first prescriptions from Kohl's during 2023. And as you can see, it takes one to two quarters to see an acceleration in that territory. This is due to the positive clinical experience generated and the initiation of peer-to-peer exchange. The last couple of quarters, we have seen the first orders from key accounts in two other regions with great potential. And even if it's early days, we do believe that these territories will also be able to take off in the coming six months and support the acceleration of sales growth in Germany. The potential of Oncopeptides has not changed. While we are putting more effort into the first cycle of our core business, we have in no way forgotten about the next step. Value drivers. During the third quarter, we signed a partnership with SCBIO Inc. and we have received a first milestone payment, the first ever for Oncopeptides, and a testament to our ambition to build sales outside of Europe. We continue to entertain discussions with potential partners in both Japan and China. We also continue to progress our pipeline in a smart and efficient way, and we remain very confident in its potential to provide value to our shareholders and patients. As for next steps, we focus our efforts on PSP, the molecule announced in the last quarter. Moving towards IND submission. Meanwhile, we continue to evaluate the best way forward for our PDC molecule. And with that, I would like to say thank you to everyone listening and hand over to the moderator for any questions.